Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 12/2016

01-12-2016 | Nonstatin Drugs (E. deGoma, Section Editor)

Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy

Authors: Ehimen C. Aneni, Esteban Escolar, Gervasio A. Lamas

Published in: Current Atherosclerosis Reports | Issue 12/2016

Login to get access

Abstract

Over the last few decades, there has been a growing body of epidemiologic evidence linking chronic toxic metal exposure to cardiovascular disease-related morbidity and mortality. The recent and unexpectedly positive findings from a randomized, double-blind, multicenter trial of metal chelation for the secondary prevention of atherosclerotic cardiovascular disease (Trial to Assess Chelation Therapy (TACT)) have focused the discussion on the role of chronic exposure to toxic metals in the development and propagation of cardiovascular disease and the role of toxic metal chelation therapy in the secondary prevention of cardiovascular disease. This review summarizes the most recent evidence linking chronic toxic metal exposure to cardiovascular disease and examines the findings of TACT.
Literature
1.
Sears ME, Sears ME. Chelation: harnessing and enhancing heavy metal detoxification—a review. Sci World J Sci World J. 2013;2013(2013):e219840.
2.
Barregard L, Sallsten G, Fagerberg B, Borné Y, Persson M, Hedblad B, et al. Blood cadmium levels and incident cardiovascular events during follow-up in a population-based cohort of Swedish adults: the Malmö Diet and Cancer study. Environ Health Perspect. 2015;30.
3.
Fagerberg B, Barregard L, Sallsten G, Forsgard N, Ostling G, Persson M, et al. Cadmium exposure and atherosclerotic carotid plaques—results from the Malmö diet and Cancer study. Environ Res. 2015;136:67–74.CrossRefPubMed
4.
Menke A, Guallar E, Cowie CC. Metals in urine and diabetes in U.S. adults. Diabetes. 2016;65(1):164–71.PubMed
5.
Solenkova NV, Newman JD, Berger JS, Thurston G, Hochman JS, Lamas GA. Metal pollutants and cardiovascular disease: mechanisms and consequences of exposure. Am Heart J. 2014;168(6):812–22.CrossRefPubMedPubMedCentral
6.
Lin J-L, Lin-Tan D-T, Hsu K-H, Yu C-C. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med. 2003;348(4):277–86.CrossRefPubMed
7.
Centers for Disease Control and Prevention (CDC). Deaths associated with hypocalcemia from chelation therapy—Texas, Pennsylvania, and Oregon, 2003–2005. MMWR Morb Mortal Wkly Rep. 2006;55(8):204–7.
8.
Agency for Toxic Substances and Diseases Registry. 2015 Priority list of hazardous substances [Internet]. 2015 [cited 2016 Apr 4]. Available from: http://​www.​atsdr.​cdc.​gov/​spl/​resources/​atsdr_​2015_​spl_​detailed_​data_​table.​pdf
9.
• Arenas I, Navas-Acien A, Lamas G. Enhanced vasculotoxic metal excretion in post-myocardial infarction patients receiving edetate disodium-based infusion. J Am Coll Cardiol. 2016;67(13_S):2125. Study demonstrating that edetate disodium increases urinary excretion of heavy metals in a post-myocardial infarction population.
10.
US EPA O. Learn about lead [Internet]. [cited 2016 Apr 5]. Available from: https://​www.​epa.​gov/​lead/​learn-about-lead#found
11.
Hanna-Attisha M, LaChance J, Sadler RC, Champney Schnepp A. Elevated blood lead levels in children associated with the Flint drinking water crisis: a spatial analysis of risk and public health response. Am J Public Health. 2015;106(2):283–90.CrossRefPubMed
12.
Erik Olson, Kristi Pullen Fedinick. What’s in your water? Flint and beyond [Internet]. Natural Resources Defense Council; 2016 [cited 2016 Aug 8]. Available from: https://​www.​nrdc.​org/​resources/​whats-your-water-flint-and-beyond
13.
Laura Ungar. Lawmakers urge the EPA to reduce its standard for lead in drinking water. USA TODAY [Internet]. 2016 [cited 2016 Jul 12]; Available from: http://​www.​usatoday.​com/​story/​news/​2016/​06/​30/​lawmakers-urge-epa-reduce-its-standard-lead-drinking-water/​86576032/​
14.
Papanikolaou NC, Hatzidaki EG, Belivanis S, Tzanakakis GN, Tsatsakis AM. Lead toxicity update. A brief review. Med Sci Monit Int Med J Exp Clin Res. 2005;11(10):RA329–36.
15.
Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation. 2006;114(13):1388–94.CrossRefPubMed
16.
17.
• Weisskopf MG, Jain N, Nie H, Sparrow D, Vokonas P, Schwartz J, et al. A prospective study of bone lead concentration and death from all causes, cardiovascular diseases, and cancer in the Department of Veterans Affairs Normative Aging Study. Circulation. 2009;120(12):1056–64. Demonstrated an association between chronic lead exposure and mortality from all cause and cardiovascular disease.CrossRefPubMedPubMedCentral
18.
Cosselman KE, Navas-Acien A, Kaufman JD. Environmental factors in cardiovascular disease. Nat Rev Cardiol. 2015;12(11):627–42.CrossRefPubMed
19.
Lamas GA, Navas-Acien A, Mark DB, Lee KL. Heavy metals, cardiovascular disease, and the unexpected benefits of chelation therapy. J Am Coll Cardiol. 2016;67(20):2411–8.CrossRefPubMed
20.
CDC. Adult Blood Lead Epidemiology and Surveillance (ABLES): program description: NIOSH Workplace safety and health topic [Internet]. [cited 2016 Aug 1]. Available from: http://​www.​cdc.​gov/​niosh/​topics/​ables/​description.​html
21.
Nash D, Magder L, Lustberg M, et al. BLood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. JAMA. 2003;289(12):1523–32.CrossRefPubMed
22.
Pirkle JL, Schwartz J, Landis JR, Harlan WR. The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Am J Epidemiol. 1985;121(2):246–58.PubMed
23.
Harlan WR, Landis JR, Schmouder RL, Goldstein NG, Harlan LC. Blood lead and blood pressure. Relationship in the adolescent and adult US population. JAMA. 1985;253(4):530–4.CrossRefPubMed
24.
Navas-Acien A, Selvin E, Sharrett AR, Calderon-Aranda E, Silbergeld E, Guallar E. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation. 2004;109(25):3196–201.CrossRefPubMed
25.
Nawrot TS, Staessen JA. Low-level environmental exposure to lead unmasked as silent killer. Circulation. 2006;114(13):1347–9.CrossRefPubMed
26.
Voors AW, Shuman MS, Johnson WD. Additive statistical effects of cadmium and lead on heart-related disease in a North Carolina autopsy series. Arch Environ Health. 1982;37(2):98–102.CrossRefPubMed
27.
Revis NW, Zinsmeister AR, Bull R. Atherosclerosis and hypertension induction by lead and cadmium ions: an effect prevented by calcium ion. Proc Natl Acad Sci U S A. 1981;78(10):6494–8.CrossRefPubMedPubMedCentral
28.
ATSDR. Public Health Statement: cadmium [Internet]. [cited 2016 Jun 1]. Available from: http://​www.​atsdr.​cdc.​gov/​phs/​phs.​asp?​id=​46&​tid=​15
29.
Hasan SA, Fariduddin Q, Ali B, Hayat S, Ahmad A. Cadmium: toxicity and tolerance in plants. J Environ Biol Acad Environ Biol India. 2009;30(2):165–74.
30.
Benavides MP, Gallego SM, Tomaro ML. Cadmium toxicity in plants. Braz J Plant Physioiogy. 2005;17(1):21–34.
31.
Richter PA, Bishop EE, Wang J, Swahn MH. Tobacco smoke exposure and levels of urinary metals in the U.S. youth and adult population: the National Health and Nutrition Examination Survey (NHANES) 1999–2004. Int J Environ Res Public Health. 2009;6(7):1930–46.CrossRefPubMedPubMedCentral
32.
Jung SY, Kim S, Lee K, Kim JY, Bae WK, Lee K, et al. Association between secondhand smoke exposure and blood lead and cadmium concentration in community dwelling women: the fifth Korea National Health and Nutrition Examination Survey (2010–2012). BMJ Open. 2015;5(7):e008218.CrossRefPubMedPubMedCentral
33.
Tellez-Plaza M, Jones MR, Dominguez-Lucas A, Guallar E, Navas-Acien A. Cadmium exposure and clinical cardiovascular disease: a systematic review. Curr Atheroscler Rep. 2013;15(10):356.CrossRefPubMed
34.
Larsson SC, Wolk A. Urinary cadmium and mortality from all causes, cancer and cardiovascular disease in the general population: systematic review and meta-analysis of cohort studies. Int J Epidemiol. 2015;20.
35.
Tellez-Plaza M, Guallar E, Fabsitz RR, Howard BV, Umans JG, Francesconi KA, et al. Cadmium exposure and incident peripheral arterial disease. Circ Cardiovasc Qual Outcomes. 2013;6(6):626–33.CrossRefPubMedPubMedCentral
36.
Hanna CW, Bloom MS, Robinson WP, Kim D, Parsons PJ, vom Saal FS, et al. DNA methylation changes in whole blood is associated with exposure to the environmental contaminants, mercury, lead, cadmium and bisphenol A, in women undergoing ovarian stimulation for IVF. Hum Reprod Oxf Engl. 2012;27(5):1401–10.CrossRef
37.
38.
Habermann E, Crowell K, Janicki P. Lead and other metals can substitute for Ca2+ in calmodulin. Arch Toxicol. 1983;54(1):61–70.CrossRefPubMed
39.
Chen C, Zhang S, Liu Z, Tian Y, Sun Q. Cadmium toxicity induces ER stress and apoptosis via impairing energy homoeostasis in cardiomyocytes. Biosci Rep [Internet]. 2015 [cited 2016 May 24];35(3). Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pmc/​articles/​PMC4613727/​
40.
41.
Klaassen CD. Heavy metals and heavy metal antagonists. In: Goodman L, Gilman A, editors. The pharmacological basis of therapeutics. New York: McGraw Hill, Medical Publishing Division; 2006.
42.
Waters RS, Bryden NA, Patterson KY, Veillon C, Anderson RA. EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc. Biol Trace Elem Res. 2001;83(3):207–21.CrossRefPubMed
43.
US Food and Drug Administration. Postmarket Drug safety information for patients and providers—questions and answers on edetate disodium [Internet]. [cited 2016 Jul 4]. Available from: http://​www.​fda.​gov/​Drugs/​DrugSafety/​PostmarketDrug SafetyInformationforPatientsandProviders/ucm113738.htm
44.
Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Rep. 2008;12:1–23.
45.
Knudtson ML, Wyse DG, Galbraith PD, Brant R, Hildebrand K, Paterson D, et al. Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA. 2002;287(4):481–6.CrossRefPubMed
46.
Guldager B, Jelnes R, Jørgensen SJ, Nielsen JS, Klaerke A, Mogensen K, et al. EDTA treatment of intermittent claudication—a double-blind, placebo-controlled study. J Intern Med. 1992;231(3):261–7.CrossRefPubMed
47.
Sloth-Nielsen J, Guldager B, Mouritzen C, Lund EB, Egeblad M, Nørregaard O, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg. 1991;162(2):122–5.CrossRefPubMed
48.
Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc. 1990;82(3):173–7.PubMedPubMedCentral
49.
van Rij AM, Solomon C, Packer SG, Hopkins WG. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation. 1994;90(3):1194–9.CrossRefPubMed
50.
Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev. 2002;4:CD002785.
51.
Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, et al. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J. 2012;163(1):7–12.CrossRefPubMedPubMedCentral
52.
Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, et al. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: the factorial group results of the Trial to Assess Chelation Therapy. Am Heart J. 2014;168(1):37–44.e5.CrossRefPubMedPubMedCentral
53.
•• Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013;309(12):1241–50. Largest trial of chelation therapy for the prevention of cardiovascular disease-related outcomes in a post-myocardial infarction population. Study’s findings have focused a discussion on the role of toxic metals in the pathogenesis of atherosclerotic CVD and have changed current guidelines on the use of chelation therapy in post-myocardial infarction patients.CrossRefPubMedPubMedCentral
54.
Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006;332(7550):1115–24.CrossRefPubMedPubMedCentral
55.
56.
•• Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 2013 Nov 19;CIRCOUTCOMES.113.000663. This study showed significant reduction in the primary outcome among participants with diabetes mellitus in the TACT trial. The findings of this study form the basis for the TACT 2 trial which seeks to reproduce the findings of TACT in a post-myocardial infarction population with established diabetes mellitus.
57.
Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AMJ, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.CrossRefPubMed
58.
A study of Evacetrapib in high-risk vascular disease—Full Text View—ClinicalTrials.gov [Internet]. Clinicaltrials.gov. [cited 2016 Aug 10]. Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT01687998
59.
Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992;267(21):14987–97.PubMed
60.
Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597–605.CrossRefPubMed
61.
Goh S-Y, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93(4):1143–52.CrossRefPubMed
62.
Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem. 2001;276(52):48967–72.CrossRefPubMed
63.
Nagai R, Murray DB, Metz TO, Baynes JW. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes. 2012;61(3):549–59.CrossRefPubMedPubMedCentral
64.
Atwood KC, Woeckner E, Baratz RS, Sampson WI. Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned. Medscape J Med. 2008;10(5):115.PubMedPubMedCentral
65.
Nissen SE. Concerns about reliability in the Trial to Assess Chelation Therapy (TACT). JAMA. 2013;309(12):1293–4.CrossRefPubMed
66.
67.
Kaul S. Are concerns about reliability in the trial to assess chelation therapy fair grounds for a hasty dismissal? An alternative perspective. Circ Cardiovasc Qual Outcomes. 2014;7(1):5–7.CrossRefPubMed
68.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–360.CrossRefPubMed
69.
Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102(9):1014–9.CrossRefPubMed
70.
Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. 2014;64(18):1929–49.CrossRefPubMed
Metadata
Title
Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy
Authors
Ehimen C. Aneni
Esteban Escolar
Gervasio A. Lamas
Publication date
01-12-2016
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 12/2016
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-016-0631-0

Other articles of this Issue 12/2016

Current Atherosclerosis Reports 12/2016 Go to the issue

Women and Ischemic Heart Disease (E. Jackson, Section Editor)

Acute Coronary Syndromes: Differences in Men and Women

Cardiovascular Disease and Stroke (S. Prabhakaran, Section Editor)

Threshold and Target for Blood Pressure Lowering in the Elderly

Statin Drugs (B. Wiggins, Section Editor)

Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?

Genetics (A. Marian, Section Editor)

Genetics—Current and Future Role in the Prevention and Management of Coronary Artery Disease

Genetics (A. Marian, Section Editor)

Transcriptomic Signature of Atherosclerosis in the Peripheral Blood: Fact or Fiction?

Vascular Biology (J. Hamilton, Section Editor)

Heterogeneity of Coronary Plaque Morphology and Natural History: Current Understanding and Clinical Significance
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits